Cipla launches ViraGen a polymerase chain reaction (Covid-19 RT-PCR) test equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
URL copied
Cipla launches ViraGen RT-PCR test.
Cipla Limited on Thursday announced the commercialisation of a polymerase chain reaction (RT-PCR) test kit âViraGen for COVID-19 in India, in partnership with Ubio Biotechnology Systems Pvt. Ltd.
ViraGen is Cipla s third offering in the Covid-19 testing segment. Cipla already has partnerships for antibody detection kit and antigen test kits.
ViraGen is a real-time detection kit approved by the ICMR (Indian Council of Medical Research) and is based on multiplex PCR technology. It helps to identify and detect SARS CoV-2 N Gene and ORF Lab Gene with the sensitivity of 98.6% and the specificity of 98.8% as compared to a standard ICMR test.
Cipla Limited on Thursday announced the commercialisation of a polymerase chain reaction (RT-PCR) test kit ViraGen for COVID-19 in India, in partnership with Ubio Biotechnology Systems Pvt. Ltd.ViraGen is Cipla s third offering in the Covid-19 .
ViraGen used for qualitative detection of SARS-CoV-2 will be manufactured by Ubio Biotechnology Systems.
Shares of the country s leading drug maker - Cipla - rose as much as 2.63 per cent to hit an intraday high of Rs 927.85 after the company launched Coronavirus detections test kit. Cipla announced the commercialization of a polymerase chain reaction (RT-PCR) test kit ViraGen for COVID-19 in India, in partnership with Ubio Biotechnology Systems Pvt. Ltd. ViraGen is Cipla s third offering in the Covid-19 testing segment. Cipla already has partnerships for antibody detection kit and antigen test kits, Cipla said in a press release.
ViraGen is a real-time detection kit approved by the ICMR (Indian Council of Medical Research) and is based on multiplex PCR technology. It helps to identify and detect SARS CoV-2 N Gene and ORF Lab Gene with the sensitivity of 98.6 per cent and the specificity of 98.8 per cent as compared to a standard ICMR test.
Cipla launches RT-PCR test kit ViraGen in India partnership with Ubio Biotech PTI
Updated : May 20, 2021, 12:42 pm IST
The company will commence supply of the COVID-19 virus detection kit from May 25, 2021
ViraGen is Cipla s third offering in the COVID-19 testing segment. (Photo: PTI)
New Delhi: Drug major Cipla on Thursday announced the commercialisation of its RT-PCR test kit ViraGen for COVID-19 in India, in partnership with Ubio Biotechnology Systems. This launch will help address the current testing services and capacity issues while reaffirming the company s ongoing expansion in the diagnostic space, Cipla said in a regulatory filing.
Cipla will launch ViraGen test kit in the country in partnership with Ubio Biotechnology Systems, the company stated.